| No. | Description | |
|---|
| 1 | "T"-Type Gas Line Filter | |
| 2 | "Y" Fitting for MSA Tube Holder | |
| 3 | "Y" GlasSeal Connector, Borosilicate Glass | |
| 4 | "Y" GlasSeal Connector, Fused Silica | |
| 5 | #15310-LN human cell line | |
| 6 | #W7079 REM human cell line | |
| 7 | ((1-(tert-Butoxycarbonyl)piperidin-4-yl)methyl)proline | |
| 8 | ((S)-3-(3,5-Bis(trifluoromethyl)phenyl)-1-(2?-(3-(3,5-bis(trifluoromethyl)phenyl)ureido)-[1,1?-binaphthalen]-2-yl)-1-isopropylu | |
| 9 | (+)-(4,6-O-Benzylidene)methyl-?-?-glucopyranoside | |
| 10 | (+)-1,2-Bis((2S,5S)-2,5-diphenylphospholano)ethane,kanata purity | |
| 11 | (+)-1,2-Bis[(2R,5R)-2,5-diethylphospholano]ethane,kanata purity | |
| 12 | (+)-1,2-Bis[(2S,5S)-2,5-diethylphospholano]benzene,Namena purity | |
| 13 | (+)-1,2-Bis[(2S,5S)-2,5-dimethylphospholano]benzene,kanata purity | |
| 14 | (+)-1-(9-Fluorenyl)ethyl chloroformate solution | |
| 15 | (+)-1-(9-Fluorenyl)ethyl chloroformate solution | |
| 16 | (+)-11-Nor-??-THC-9-carboxylic acid glucuronide solution | |
| 17 | (+)-2,2?-Isopropylidenebis[(4R)-4-phenyl-2-oxazoline] | |
| 18 | (+)-2,3-Dibenzoyl-?-tartaric acid | |
| 19 | (+)-2,3-Dibenzoyl-?-tartaric acid | |
| 20 | (+)-2-Carene | |
| 21 | (+)-3-(Trifluoroacetyl)camphor | |
| 22 | (+)-3-Bromocamphor,purum, ?97.0% (sum of enantiomers, GC) | |
| 23 | (+)-3-Carene,analytical standard | |
| 24 | (+)-4-Cholesten-3-one | |
| 25 | (+)-6-Aminopenicillanic acid | |
| 26 | (+)-6-Aminopenicillanic acid | |
| 27 | (+)-?-3-Carene,phyproof® Reference Substance | |
| 28 | (+)-?-Alliin,analytical standard | |
| 29 | (+)-?-Cedrene,?95.0% (sum of enantiomers, GC) | |
| 30 | (+)-?-Decalactone,natural, ?97%, FG | |
| 31 | (+)-?-Methyl-4-carboxyphenylglycine,solid | |
| 32 | (+)-?-Pinene | |
| 33 | (+)-?-Pinene | |
| 34 | (+)-?-Pinene,analytical standard | |
| 35 | (+)-?-Pinene,analytical standard | |
| 36 | (+)-?-Pinene,certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland | |
| 37 | (+)-?-Terpineol,analytical standard | |
| 38 | (+)-?-Tocopherol | |
| 39 | (+)-?-Tocopherol acetate | |
| 40 | (+)-?-Tocopherol acetate | |
| 41 | (+)-?-Tocopherol,?96% (HPLC) | |
| 42 | (+)-?-Tocopherol,analytical standard | |
| 43 | (+)-?-Tocopherol,from vegetable oil, Type V, ~1000 IU/g | |
| 44 | (+)-?-Tocopherol,Type VI, from vegetable oil, liquid (?0.88M based on potency, density and molecular wt.), BioReagent, suitable | |
| 45 | (+)-Abscisic acid | |
| 46 | (+)-Abscisic Acid | |
| 47 | (+)-Abscisic acid | |
| 48 | (+)-Anabasine hydrochloride solution | |
| 49 | (+)-Arabinogalactan,?80% (HPLC), from larch wood | |
| 50 | (+)-Bicuculline | |
| 51 | (+)-Bicuculline,?97.0% (TLC) | |
| 52 | (+)-Bicuculline,?97.0% (TLC) | |
| 53 | (+)-Bicuculline,phyproof® Reference Substance | |
| 54 | (+)-Biotin 4-nitrophenyl ester | |
| 55 | (+)-Biotin hydrazide | |
| 56 | (+)-Biotin N-hydroxysuccinimide ester | |
| 57 | (+)-Biotinamidohexanoic acid hydrazide | |
| 58 | (+)-Bis[(R)-1-phenylethyl]amine | |
| 59 | (+)-Blebbistatin,The inactive enantiomer of (±)-Blebbistatin. | |
| 60 | (+)-Borneol | |
| 61 | (+)-Borneol solution | |
| 62 | (+)-Borneol,analytical standard | |
| 63 | (+)-Brefeldin A, Eupenicillium brefeldianum | |
| 64 | (+)-Brefeldin A, Eupenicillium brefeldianum | |
| 65 | (+)-Butaclamol hydrochloride | |
| 66 | (+)-Camphor-10-sulfonic acid | |
| 67 | (+)-Carvone,analytical standard | |
| 68 | (+)-Carvone,analytical standard | |
| 69 | (+)-Carvone,certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland | |
| 70 | (+)-Carvone,phyproof® Reference Substance | |
| 71 | (+)-Catechin 5-gallate | |
| 72 | (+)-Catechin hydrate | |
| 73 | (+)-Catechin hydrate | |
| 74 | (+)-Catechin hydrate | |
| 75 | (+)-Catechin,analytical standard | |
| 76 | (+)-Catechin,Pharmaceutical Secondary Standard; Certified Reference Material | |
| 77 | (+)-Catechin,phyproof® Reference Substance | |
| 78 | (+)-Catechin,United States Pharmacopeia (USP) Reference Standard | |
| 79 | (+)-Cedrol,?99.0% (sum of enantiomers, GC) | |
| 80 | (+)-Chloromethyl menthyl ether | |
| 81 | (+)-Cinchonine | |
| 82 | (+)-Cinchonine,for resolution of racemates for synthesis | |
| 83 | (+)-Cinchonine,for resolution of racemates for synthesis | |
| 84 | (+)-Cinchonine,phyproof® Reference Substance | |
| 85 | (+)-cis-Diltiazem hydrochloride | |
| 86 | (+)-CP-99994 dihydrochloride | |
| 87 | (+)-Cuparene,?99.0% (sum of enantiomers, GC) | |
| 88 | (+)-Dehydroabietylamine,technical grade, 60% | |
| 89 | (+)-Diethyl ?-tartrate | |
| 90 | (+)-Dihydrocarveol,purum, mixture of isomers, ?95.0% (sum of enantiomers, GC) | |
| 91 | (+)-Dihydrocarvone, mixture of isomers | |
| 92 | (+)-Dihydrocarvone,mixture of isomers | |
| 93 | (+)-Dihydrocinchonine,phyproof® Reference Substance | |
| 94 | (+)-Dihydroquinidine,phyproof® Reference Substance | |
| 95 | (+)-Dimethyl 2,3-O-isopropylidene-?-tartrate | |
| 96 | (+)-Dimethyl ?-tartrate | |
| 97 | (+)-DIP-Chloride™,90-105% (approx.) | |
| 98 | (+)-Etomoxir sodium salt hydrate | |
| 99 | (+)-Eudesmin,phyproof® Reference Substance | |
| 100 | (+)-Fenchone,analytical standard | |
| 101 | (+)-Fenchone,phyproof® Reference Substance | |
| 102 | (+)-Fenchone,purum, ?98.0% (sum of enantiomers, GC) | |
| 103 | (+)-Fenfluramine hydrochloride | |
| 104 | (+)-Garcinia acid | |
| 105 | (+)-Isocorydine hydrochloride | |
| 106 | (+)-Isomenthol,phyproof® Reference Substance | |
| 107 | (+)-Isopulegol,analytical standard | |
| 108 | (+)-JQ1,?98% (HPLC) | |
| 109 | (+)-Lariciresinol,?95.0% (HPLC) | |
| 110 | (+)-Limonene 1,2-epoxide | |
| 111 | (+)-Limonene oxide, mixture of cis and trans | |
| 112 | (+)-Longifolene,phyproof® Reference Substance | |
| 113 | (+)-Lupanine hydrochloride | |
| 114 | (+)-Magnesium ?-ascorbate | |
| 115 | (+)-Marmesin,phyproof® Reference Substance | |
| 116 | (+)-Menthofuran,analytical standard | |
| 117 | (+)-Menthofuran,phyproof® Reference Substance | |
| 118 | (+)-Menthofuran,primary reference standard | |
| 119 | (+)-Menthone,analytical standard | |
| 120 | (+)-Methamphetamine hydrochloride | |
| 121 | (+)-Methyl ?-lactate | |
| 122 | (+)-MK-801 hydrogen maleate | |
| 123 | (+)-MK-801 hydrogen maleate | |
| 124 | (+)-Muscarine chloride | |
| 125 | (+)-N,N?-Diallyltartramide | |
| 126 | (+)-N-3-Benzylnirvanol,?98% (HPLC), powder | |
| 127 | (+)-N-Allylnormetazocine hydrochloride | |
| 128 | (+)-N-Boc-?-?-phenylglycinol | |
| 129 | (+)-Nootkatone,?99.0% (GC) | |
| 130 | (+)-Norfenfluramine hydrochloride | |
| 131 | (+)-Norpropoxyphene maleate solution | |
| 132 | (+)-O,O?-Di-p-toluoyl-?-tartaric acid | |
| 133 | (+)-O,O?-Di-pivaloyl-?-tartaric acid | |
| 134 | (+)-O,O?-Diacetyl-?-tartaric anhydride | |
| 135 | (+)-Pentazocine,solid | |
| 136 | (+)-Peucedanol,phyproof® Reference Substance | |
| 137 | (+)-PI Reagent | |
| 138 | (+)-Pinoresinol,phyproof® Reference Substance | |
| 139 | (+)-Piscidic acid | |
| 140 | (+)-Praeruptorin A | |
| 141 | (+)-Propoxyphene solution | |
| 142 | (+)-Pseudoephedrine hydrochloride | |
| 143 | (+)-PSI Reagent | |
| 144 | (+)-Pulegone,analytical standard | |
| 145 | (+)-Pulegone,phyproof® Reference Substance | |
| 146 | (+)-Pulegone,primary reference standard | |
| 147 | (+)-Quinidine,phyproof® Reference Substance | |
| 148 | (+)-S-Trityl-?-cysteine | |
| 149 | (+)-Secoisolariciresinol,phyproof® Reference Substance | |
| 150 | (+)-Sodium ?-ascorbate | |
| 151 | (+)-Sodium ?-ascorbate | |
| 152 | (+)-Sodium ?-ascorbate | |
| 153 | (+)-Sparteine | |
| 154 | (+)-Sparteine,?98.0% (GC) | |
| 155 | (+)-Taxifolin,phyproof® Reference Substance | |
| 156 | (+)-Terpinen-4-ol,analytical standard | |
| 157 | (+)-Thalidomide,?98% (HPLC), powder | |
| 158 | (+)-trans-Chrysanthemic acid | |
| 159 | (+)-Tubocurarine Chloride | |
| 160 | (+)-Tubocurarine chloride pentahydrate | |
| 161 | (+)-Usnic acid | |
| 162 | (+)-Usnic acid | |
| 163 | (+)-Valencene,analytical standard | |
| 164 | (+)-Vestitol,?98% (HPLC) | |
| 165 | (+/-)-8-Prenylnaringenin,Plant-derived estrogen receptor ligand | |
| 166 | (+/-)-Atenolol | |
| 167 | (+/-)-Clopidogrel Hydrogensulfate | |
| 168 | (+/-)-Cloprostenol sodium salt hydrate | |
| 169 | (+/-)-JQ1,?98% (HPLC) | |
| 170 | (+\-)-4-Hydroxy-3-methoxymandelic Acid-D? (ring-D?) solution | |
| 171 | (-)-11-NOR-9-CARBOXY-DELTA8-THC GLUCURON | |
| 172 | (-)-11-nor-9-Carboxy-delta8-THC solution | |
| 173 | (-)-11-Nor-delta9-THC- 9-carboxylic acid glucuronide solution | |
| 174 | (-)-2-(2-Naphthylmethoxy)isopinocampheol | |
| 175 | (-)-?-Bisabolol,natural, ?95%, FG | |
| 176 | (-)-?-Pinene,natural, ?97%, FCC, FG | |
| 177 | (-)-Asarinin,phyproof® Reference Substance | |
| 178 | (-)-Bilobalide,phyproof® Reference Substance | |
| 179 | (-)-Blebbistatin,The active enantiomer of (±)-Blebbistatin that accounts for the inhibitory activity towards ATPase and | |
| 180 | (-)-Brucine,for resolution of racemates for synthesis | |
| 181 | (-)-Cinchonidine,phyproof® Reference Substance | |
| 182 | (-)-Cytisine | |
| 183 | (-)-delta8-THC-D? solution | |
| 184 | (-)-delta9-THC-O-beta-D-glucuronide sodium salt solution | |
| 185 | (-)-Dihydroquinine,phyproof® Reference Substance | |
| 186 | (-)-Englerin B | |
| 187 | (-)-exo-THC-D? solution | |
| 188 | (-)-Fenchone,phyproof® Reference Substance | |
| 189 | (-)-Guaiol solution | |
| 190 | (-)-Hydroxycitric acid lactone | |
| 191 | (-)-JQ1,?95% (HPLC) | |
| 192 | (-)-Lupinine,phyproof® Reference Substance | |
| 193 | (-)-Matairesinol,phyproof® Reference Substance | |
| 194 | (-)-Menthol,for synthesis | |
| 195 | (-)-Nicotine,for synthesis | |
| 196 | (-)-Nicotine,for synthesis | |
| 197 | (-)-Nicotine,for synthesis | |
| 198 | (-)-Nicotine,for synthesis | |
| 199 | (-)-Nicotine,for synthesis | |
| 200 | (-)-Quinic acid | |
